Loading clinical trials...
Loading clinical trials...
A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Conditions
Interventions
TR-701 200 mg
TR-701 300 mg
+1 more
Locations
12
United States
Trius Study Site #011
Dothan, Alabama, United States
Trius Study site #001
Chula Vista, California, United States
Trius Study Site #009
Long Beach, California, United States
Trius Study site #002
Oceanside, California, United States
Trius Study site #010
Pasadena, California, United States
Trius Study site 007
San Francisco, California, United States
Start Date
September 17, 2008
Primary Completion Date
February 24, 2009
Completion Date
February 24, 2009
Last Updated
November 25, 2019
NCT03643952
NCT00711802
NCT00785200
NCT00388310
NCT00488345
NCT00257036
Lead Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions